Association of the gut microbiome and metabolome with wheeze frequency in childhood asthma - 04/08/22
, Scott T. Weiss, MD, MS a, ⁎ Abstract |
Background |
While the microbiome has an established role in asthma development, less is known about its contribution to morbidity in children with asthma.
Objective |
In this ancillary study of the Vitamin D Antenatal Asthma Reduction Trial (VDAART), we analyzed the gut microbiome and metabolome of wheeze frequency in children with asthma.
Methods |
Bacterial 16S ribosomal RNA microbiome and untargeted metabolomic profiling were performed on fecal samples collected from 3-year-old children with parent-reported physician-diagnosed asthma. We analyzed wheeze frequency by calculating the proportion of quarterly questionnaires administered between ages 3 and 5 years in which parents reported the child had wheezed (wheeze proportion). Taxa and metabolites associated with wheeze were analyzed by identifying log fold changes with respect to wheeze frequency and correlation/linear regression analyses, respectively. Microbe–metabolite and microbe–microbe correlation networks were compared between subjects with high and low wheeze proportion.
Results |
Specific taxa, including the genus Veillonella and histidine pathway metabolites, were enriched in subjects with high wheeze proportion. Among wheeze-associated taxa, Veillonella and Oscillospiraceae UCG-005, which was inversely associated with wheeze, were correlated with the greatest number of fecal metabolites. Microbial networks were similar between subjects with low versus high wheeze frequency.
Conclusion |
Gut microbiome features are associated with wheeze frequency in children with asthma, suggesting an impact of the gut microbiome on morbidity in childhood asthma.
Il testo completo di questo articolo è disponibile in PDF.Graphical abstract |
Key words : Microbiome, metabolomics, asthma, wheeze
Abbreviations used : AA, CI, FDR, HMDB, ICS, PERMANOVA, RA, rRNA, SparCC, UCG, VDAART
Mappa
| The first 2 authors contributed equally to this article, and both should be considered first author. S.D. is currently affiliated with Excerpta Medica, Amsterdam, The Netherlands. |
|
| The Vitamin D Antenatal Asthma Reduction Trial (VDAART) was funded by U01HL091528 from the National Heart, Lung, and Blood Institute. Additional funding came from National Institutes of Health grants R01HL108818, R01HL123915, R01HL141826, and K08 HL148178, and ECHO grant OD023268. |
|
| Disclosure of potential conflict of interest: A. A. Litonjua has received author royalties from UpToDate Inc. S. T. Weiss has received royalties from UpToDate Inc. L. B. Bacharier participates on the Data Safety Monitoring Board of DBV Technologies. A. Beigelman holds stock from DBV Technologies, is a consultant for AstraZeneca and Raffa, and has received speaking honoraria from AstraZeneca, Novartis, and Sanofi. R. S. Zeiger is a consultant for AstraZeneca, DBV Technologies, Genentech Inc, GlaxoSmithKline, Merck & Co, Novartis, Quest Diagnostics, Regeneron/Sanofi, and Teva Pharmaceuticals, and has received research support from ALK Pharmaceuticals, AstraZeneca, Genentech Inc, GlaxoSmithKline, the National Heart, Lung, and Blood Institute, MedImmune, Merck, and Teva Pharmaceuticals. J. Lasky-Su is a consultant to Metabolon Inc. G. T. O’Connor is a coinvestigator on a grant from Janssen Pharmaceuticals to Boston University that funds a study of the pathogenesis of chronic obstructive pulmonary disease. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 150 - N° 2
P. 325-336 - Agosto 2022 Ritorno al numero
Articolo precedente
- Preexisting comorbidities shape the immune response associated with severe COVID-19
- Stefanie Kreutmair, Manuel Kauffmann, Susanne Unger, Florian Ingelfinger, Nicolás Gonzalo Núñez, Chiara Alberti, Donatella De Feo, Sinduya Krishnarajah, Ekaterina Friebel, Can Ulutekin, Sepideh Babaei, Benjamin Gaborit, Mirjam Lutz, Nicole Puertas Jurado, Nisar P. Malek, Siri Göpel, Peter Rosenberger, Helene A. Häberle, Ikram Ayoub, Sally Al-Hajj, Manfred Claassen, Roland Liblau, Guillaume Martin-Blondel, Michael Bitzer, Antoine Roquilly, Burkhard Becher
- IL-17A mediates pyroptosis via the ERK pathway and contributes to steroid resistance in CRSwNP
- Yue Li, Li-Hong Chang, Wei-Qiang Huang, Hong-Wei Bao, Xia Li, Xiao-Hong Chen, Hao-Tian Wu, Zhou-Zhou Yao, Zi-Zhen Huang, Samuel E. Weinberg, De-Yu Fang, Ya-Na Zhang, Ge-Hua Zhang
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?